GSK plc (NYSE:GSK) Stock Position Lifted by Sigma Planning Corp

Sigma Planning Corp boosted its stake in GSK plc (NYSE:GSK) by 1.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 34,819 shares of the pharmaceutical company’s stock after buying an additional 630 shares during the quarter. Sigma Planning Corp’s holdings in GSK were worth $1,178,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. FMR LLC boosted its position in GSK by 8.3% during the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after purchasing an additional 2,224,345 shares during the last quarter. Fisher Asset Management LLC lifted its holdings in shares of GSK by 4.9% during the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after buying an additional 870,449 shares during the last quarter. Clifford Capital Partners LLC grew its stake in shares of GSK by 14.3% in the 3rd quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock valued at $16,747,000 after buying an additional 51,378 shares in the last quarter. Cerity Partners LLC increased its holdings in GSK by 61.8% in the third quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock worth $17,728,000 after buying an additional 165,556 shares during the last quarter. Finally, Natixis Advisors LLC raised its position in GSK by 20.0% during the third quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock valued at $20,460,000 after acquiring an additional 83,433 shares in the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

Wall Street Analysts Forecast Growth

GSK has been the subject of several recent research reports. Morgan Stanley initiated coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and decreased their price target for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Seven research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Price Performance

Shares of NYSE:GSK opened at $37.03 on Tuesday. The company has a market cap of $76.74 billion, a price-to-earnings ratio of 23.29, a PEG ratio of 1.12 and a beta of 0.64. The business has a 50 day moving average price of $34.67 and a 200 day moving average price of $37.32. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.92.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Research analysts predict that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be given a $0.3932 dividend. This represents a $1.57 annualized dividend and a yield of 4.25%. This is a positive change from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, February 21st. GSK’s dividend payout ratio (DPR) is currently 98.74%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.